Iovance Biotherapeutics, Inc. (IOVA)

US — Healthcare Sector
Peers: CVAC  KRYS  VIR  PPCB  FATE  TWST  CDNA  PSNL  VCYT 

Automate Your Wheel Strategy on IOVA

With Tiblio's Option Bot, you can configure your own wheel strategy including IOVA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol IOVA
  • Rev/Share 0.722
  • Book/Share 2.0881
  • PB 1.2164
  • Debt/Equity 0.0761
  • CurrentRatio 3.2713
  • ROIC -0.5225

 

  • MktCap 919109160.0
  • FreeCF/Share -0.9672
  • PFCF -2.8408
  • PE -2.1791
  • Debt/Assets 0.0586
  • DivYield 0
  • ROE -0.5287

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 4
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade IOVA Goldman Neutral Sell -- $1 July 15, 2025
Downgrade IOVA UBS Buy Neutral -- $2 May 16, 2025
Downgrade IOVA Truist Buy Hold -- -- May 12, 2025
Downgrade IOVA Citizens JMP Mkt Outperform Market Perform -- -- May 9, 2025

News

IOVA LAWSUIT ALERT: Levi & Korsinsky Notifies Iovance Biotherapeutics, Inc. Investors - Lead Plaintiff Deadline July 14, 2025
IOVA
Published: May 20, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 20, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=149473&wire=1&utm_campaign=7 or contact Joseph E. Levi, Esq.

Read More
image for news IOVA LAWSUIT ALERT: Levi & Korsinsky Notifies Iovance Biotherapeutics, Inc. Investors - Lead Plaintiff Deadline July 14, 2025
FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC Continues Lead Plaintiff Search for Iovance Biotherapeutics, Inc. (IOVA) Securities Fraud Class Action
IOVA
Published: May 20, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK and NEW ORLEANS, May 20, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with losses in excess of $100,000 that they have until July 15, 2025 to file lead plaintiff applications in a securities class action lawsuit against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NasdaqGM: IOVA), if they purchased the Company's securities between May 9, 2024 and May 8, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.

Read More
image for news FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC Continues Lead Plaintiff Search for Iovance Biotherapeutics, Inc. (IOVA) Securities Fraud Class Action
Down More Than 75% This Year, Should Investors Throw in the Towel on Iovance Biotherapeutics Stock?
IOVA
Published: May 20, 2025 by: The Motley Fool
Sentiment: Neutral

Entering trading this week, shares of Iovance Biotherapeutics (IOVA 4.10%) have crashed by nearly 78% since the start of the year. It has been an abysmal start to 2025 for a company that does possess some attractive long-term growth prospects.

Read More
image for news Down More Than 75% This Year, Should Investors Throw in the Towel on Iovance Biotherapeutics Stock?
Levi & Korsinsky Notifies Iovance Biotherapeutics, Inc. (IOVA) Investors - Lead Plaintiff Deadline on July 14, 2025
IOVA
Published: May 20, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 20, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=149453&wire=1&utm_campaign=14 or contact Joseph E. Levi, Esq.

Read More
image for news Levi & Korsinsky Notifies Iovance Biotherapeutics, Inc. (IOVA) Investors - Lead Plaintiff Deadline on July 14, 2025
Levi & Korsinsky Notifies Iovance Biotherapeutics, Inc. (IOVA) Shareholders of Class Action Lawsuit and July 14, 2025 Deadline
IOVA
Published: May 20, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 20, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=149450&wire=1&utm_campaign=15 or contact Joseph E. Levi, Esq.

Read More
image for news Levi & Korsinsky Notifies Iovance Biotherapeutics, Inc. (IOVA) Shareholders of Class Action Lawsuit and July 14, 2025 Deadline
ROSEN, A TOP - RANKED INVESTOR RIGHTS FIRM, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IOVA
IOVA
Published: May 20, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK CITY, NY / ACCESS Newswire / May 20, 2025 / WHY: New York, N.Y., May 20, 2025.

Read More
image for news ROSEN, A TOP - RANKED INVESTOR RIGHTS FIRM, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IOVA
Deadline Approaching: Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
IOVA
Published: May 20, 2025 by: Business Wire
Sentiment: Neutral

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming July 14, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA) securities between May 9, 2024 and May 8, 2025, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN IOVANCE BIOTHERAPEUTICS, INC. (IOVA), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIP.

Read More
image for news Deadline Approaching: Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
Securities Lawsuit Alert: Iovance Biotherapeutics, Inc. (IOVA) - Contact Levi & Korsinsky Before July 14, 2025
IOVA
Published: May 20, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 20, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=149414&wire=1&utm_campaign=3 or contact Joseph E. Levi, Esq.

Read More
image for news Securities Lawsuit Alert: Iovance Biotherapeutics, Inc. (IOVA) - Contact Levi & Korsinsky Before July 14, 2025
IOVA NOTIFICATION: A Class Action Has Been Filed on Behalf of Iovance Biotherapeutics, Inc. Investors - Contact BFA Law by July 14 Legal Deadline
IOVA
Published: May 20, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK CITY, NY / ACCESS Newswire / May 20, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit.

Read More
image for news IOVA NOTIFICATION: A Class Action Has Been Filed on Behalf of Iovance Biotherapeutics, Inc. Investors - Contact BFA Law by July 14 Legal Deadline
Contact Levi & Korsinsky by July 14, 2025 to Join Class Action Against Iovance Biotherapeutics, Inc. (IOVA)
IOVA
Published: May 20, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 20, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=149407&wire=1&utm_campaign=10 or contact Joseph E. Levi, Esq.

Read More
image for news Contact Levi & Korsinsky by July 14, 2025 to Join Class Action Against Iovance Biotherapeutics, Inc. (IOVA)
Class Action Filed Against Iovance Biotherapeutics, Inc. (IOVA) Seeking Recovery for Investors - Contact The Gross Law Firm
IOVA
Published: May 19, 2025 by: PRNewsWire
Sentiment: Neutral

NEW YORK , May 19, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA). Shareholders who purchased shares of IOVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Read More
image for news Class Action Filed Against Iovance Biotherapeutics, Inc. (IOVA) Seeking Recovery for Investors - Contact The Gross Law Firm
July 14, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against IOVA
IOVA
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) of a class action securities lawsuit.

Read More
image for news July 14, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against IOVA
Levi & Korsinsky Urges Iovance (IOVA) Shareholders to Act Before Lead Plaintiff Deadline July 14, 2025
IOVA
Published: May 19, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 19, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=149244&wire=1&utm_campaign=19 or contact Joseph E. Levi, Esq.

Read More
image for news Levi & Korsinsky Urges Iovance (IOVA) Shareholders to Act Before Lead Plaintiff Deadline July 14, 2025
IOVA LAWSUIT ALERT: Levi & Korsinsky Notifies Iovance Biotherapeutics, Inc. Investors - Lead Plaintiff Deadline July 14, 2025
IOVA
Published: May 19, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 19, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=149239&wire=1&utm_campaign=7 or contact Joseph E. Levi, Esq.

Read More
image for news IOVA LAWSUIT ALERT: Levi & Korsinsky Notifies Iovance Biotherapeutics, Inc. Investors - Lead Plaintiff Deadline July 14, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA
IOVA
Published: May 19, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK CITY, NY / ACCESS Newswire / May 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ:IOVA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA
Law Offices of Frank R. Cruz Encourages Iovance Biotherapeutics, Inc. (IOVA) Investors To Inquire About Securities Fraud Class Action
IOVA
Published: May 19, 2025 by: Business Wire
Sentiment: Neutral

LOS ANGELES--(BUSINESS WIRE)--Law Offices of Frank R. Cruz Encourages Iovance Biotherapeutics, Inc. (IOVA) Investors To Inquire About Securities Fraud Class Action.

Read More
image for news Law Offices of Frank R. Cruz Encourages Iovance Biotherapeutics, Inc. (IOVA) Investors To Inquire About Securities Fraud Class Action
Investors in Iovance Biotherapeutics, Inc. (IOVA): Protect Your Rights - Contact Levi & Korsinsky Before July 14, 2025
IOVA
Published: May 19, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 19, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=149222&wire=1&utm_campaign=11 or contact Joseph E. Levi, Esq.

Read More
image for news Investors in Iovance Biotherapeutics, Inc. (IOVA): Protect Your Rights - Contact Levi & Korsinsky Before July 14, 2025
IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit
IOVA
Published: May 19, 2025 by: PRNewsWire
Sentiment: Neutral

NEW YORK , May 19, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) securities between May 9, 2024 and May 8, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.

Read More
image for news IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit
Did You Lose Money on Iovance Biotherapeutics, Inc. (IOVA)? Levi & Korsinsky Urges Investors to Act Before July 14, 2025
IOVA
Published: May 19, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 19, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=149151&wire=1&utm_campaign=28 or contact Joseph E. Levi, Esq.

Read More
image for news Did You Lose Money on Iovance Biotherapeutics, Inc. (IOVA)? Levi & Korsinsky Urges Investors to Act Before July 14, 2025
IOVA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Iovance Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
IOVA
Published: May 19, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK CITY, NY / ACCESS Newswire / May 19, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. ("Iovance" or "the Company") (NASDAQ:IOVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Iovance securities between May 9, 2024 and May 8, 2025, both dates inclusive (the "Class Period").

Read More
image for news IOVA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Iovance Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Levi & Korsinsky Notifies Iovance Biotherapeutics, Inc. (IOVA) Shareholders of Class Action Lawsuit and July 14, 2025 Deadline
IOVA
Published: May 18, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 18, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=149114&wire=1&utm_campaign=15 or contact Joseph E. Levi, Esq.

Read More
image for news Levi & Korsinsky Notifies Iovance Biotherapeutics, Inc. (IOVA) Shareholders of Class Action Lawsuit and July 14, 2025 Deadline
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IOVA
IOVA
Published: May 18, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, May 18, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) securities between May 9, 2024 and May 8, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 14, 2025.

Read More
image for news ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IOVA
Levi & Korsinsky Urges Iovance Biotherapeutics, Inc. (IOVA) Shareholders to Act Before Lead Plaintiff Deadline July 14, 2025
IOVA
Published: May 18, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 18, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=149088&wire=1&utm_campaign=18 or contact Joseph E. Levi, Esq.

Read More
image for news Levi & Korsinsky Urges Iovance Biotherapeutics, Inc. (IOVA) Shareholders to Act Before Lead Plaintiff Deadline July 14, 2025
Class Action Alert: Levi & Korsinsky Reminds Iovance (IOVA) Investors of July 14, 2025 Deadline
IOVA
Published: May 17, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 17, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=148992&wire=1&utm_campaign=17 or contact Joseph E. Levi, Esq.

Read More
image for news Class Action Alert: Levi & Korsinsky Reminds Iovance (IOVA) Investors of July 14, 2025 Deadline
Levi & Korsinsky Notifies Iovance Biotherapeutics, Inc. (IOVA) Investors - Lead Plaintiff Deadline on July 14, 2025
IOVA
Published: May 16, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 16, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=148926&wire=1&utm_campaign=14 or contact Joseph E. Levi, Esq.

Read More
image for news Levi & Korsinsky Notifies Iovance Biotherapeutics, Inc. (IOVA) Investors - Lead Plaintiff Deadline on July 14, 2025
Contact Levi & Korsinsky by July 14, 2025 to Join Class Action Against Iovance Biotherapeutics, Inc. (IOVA)
IOVA
Published: May 16, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 16, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=148912&wire=1&utm_campaign=10 or contact Joseph E. Levi, Esq.

Read More
image for news Contact Levi & Korsinsky by July 14, 2025 to Join Class Action Against Iovance Biotherapeutics, Inc. (IOVA)
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Iovance Biotherapeutics, Inc. (IOVA) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
IOVA
Published: May 16, 2025 by: GlobeNewsWire
Sentiment: Neutral

ATLANTA, May 16, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information about Iovance's business, operations, and prospects, including allegations that: (1) new Authorized Treatment Centers (“ATCs”) were experiencing longer timelines to begin treating patients with Amtagvi; (2) Iovance's sales team and new ATCs were ineffective in patient identification and patient selection for Amtagvi, leading to higher patient drop-offs; and (3) the foregoing dynamics led to higher costs and …

Read More
image for news INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Iovance Biotherapeutics, Inc. (IOVA) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
IOVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Iovance Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
IOVA
Published: May 16, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. ("Iovance" or "the Company") (NASDAQ:IOVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Iovance securities between May 9, 2024 and May 8, 2025, both dates inclusive (the "Class Period").

Read More
image for news IOVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Iovance Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Join Class Action to Recover Losses from Iovance Biotherapeutics, Inc. (IOVA) - Contact Levi & Korsinsky Before July 14, 2025
IOVA
Published: May 16, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 16, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=148904&wire=1&utm_campaign=31 or contact Joseph E. Levi, Esq.

Read More
image for news Join Class Action to Recover Losses from Iovance Biotherapeutics, Inc. (IOVA) - Contact Levi & Korsinsky Before July 14, 2025
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Iovance Biotherapeutics, Inc. (IOVA) And Encourages Stockholders to Reach Out
IOVA
Published: May 16, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Iovance Biotherapeutics, Inc. ("Iovance" or "the Company") (NASDAQ:IOVA). Investors who purchased Iovance securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/IOVA.

Read More
image for news Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Iovance Biotherapeutics, Inc. (IOVA) And Encourages Stockholders to Reach Out

About Iovance Biotherapeutics, Inc. (IOVA)

  • IPO Date 2010-10-15
  • Website https://www.iovance.com
  • Industry Biotechnology
  • CEO Frederick G. Vogt
  • Employees 838

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.